J. Verweij

发表

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors

P. Sonneveld, P. Sonneveld, J. Verweij, 2004, Cancer Chemotherapy and Pharmacology.

A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

J. Verweij, W. Loos, J. Verweij, 2006, Cancer Chemotherapy and Pharmacology.

Phase I study of the aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on Days 1, 8, 15 every 4 wks in patients with advanced solid tumors

Maurizio Rocchetti, J. Verweij, J. Nortier, 2008 .

Innovation in oncology clinical trial design.

F. Bretz, I. Radtke, F. Bretz, 2019, Cancer treatment reviews.

Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure

Patrick Schöffski, Paolo G. Casali, G. Demetri, 2008 .

13LBA Improved overall survival by adding regional hyperthermia to neo-adjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma (HR-STS): Long-term outcomes of the EORTC 62961/ESHO randomized phase III study

Ulrich Mansmann, Claus Belka, Peter Hohenberger, 2015 .

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

J. Verweij, J. Schellens, P. Schmitz, 1996, British Journal of Cancer.

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.

M. J. van den Bent, J. Verweij, W. van Putten, 1997, British Journal of Cancer.

Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

J. Verweij, J. Schellens, G. Stoter, 1994, British Journal of Cancer.